Ivonescimab with chemo before surgery for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding a new drug called Ivonescimab to standard chemotherapy (paclitaxel and cisplatin) given before a hysterectomy in women with cervical cancer stage IB2 or IIA1 (tumor size 2-4 cm). The goal is to see if this combination improves outcomes compared to chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer stage IB2 or IIA1 with a tumor between 2 and 4 cm, confirmed by MRI.
- Your tumor is one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- You are between 18 and 75 years old.
- You feel well enough for daily activities (ECOG score 0 or 1).
- You have not received any prior treatment for this cancer.
- You agree to use effective birth control during the study and for 6 months after if you could become pregnant, and you are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
This trial tests if giving immunotherapy with chemotherapy before surgery can shrink tumors in people with advanced cervical cancer. It is for those who have not had any prior treatment.
This trial tests a new drug called ivonescimab combined with chemotherapy given before standard chemoradiation for women with locally advanced cervical cancer that has a high risk of coming back. The goal is to see if this approach can improve outcomes.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
Hear when a new Cervical Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.